News
2 Top Biotech Stocks to Buy Right Now
It's been a rough year for the biotech industry, which as a whole has substantially lagged the broader market. Just look at the performance of the SPDR S&P Biotech ETF, an industry benchmark. What's
2 Top Biotech Stocks to Buy Right Now
It's been a rough year for the biotech industry, which as a whole has substantially lagged the broader market. Just look at the performance of the SPDR S&P Biotech ETF, an industry benchmark. What's
Got $5,000? Get the Most Bang for Your Buck With These 4%-Plus Dividend Yield Stocks
The average stock in the S&P 500 has a dividend that only yields 1.6%. However, investors can secure much higher yields than that without taking on much extra risk. If you've got $5,000 that you can
Got $5,000? Get the Most Bang for Your Buck With These 4%-Plus Dividend Yield Stocks
The average stock in the S&P 500 has a dividend that only yields 1.6%. However, investors can secure much higher yields than that without taking on much extra risk. If you've got $5,000 that you can
The Alzheimer's Drug Market Is Heating Up. Should You Buy the Leading Contenders' Stocks?
It's a no-brainer to invest in businesses that are making headway in the growth markets of the future. In biopharma, therapies to treat or prevent Alzheimer's disease constitute one such growth
The Alzheimer's Drug Market Is Heating Up. Should You Buy the Leading Contenders' Stocks?
It's a no-brainer to invest in businesses that are making headway in the growth markets of the future. In biopharma, therapies to treat or prevent Alzheimer's disease constitute one such growth
The Alzheimer's Drug Market Is Heating Up. Should You Buy the Leading Contenders' Stocks?
It's a no-brainer to invest in businesses that are making headway in the growth markets of the future. In biopharma, therapies to treat or prevent Alzheimer's disease constitute one such growth
AbbVie's $21 Billion Drug Humira Is on the Decline. Should You Still Buy This Dividend Stock?
For the past couple of years, investors looked ahead to one particular thing with dread: AbbVie's (NYSE: ABBV) blockbuster immunology drug facing competition. After all, at its peak, Humira brought
EQS-News: Invitation to MorphoSys’ Third Quarter and First Nine Months 2023 Financial Results Conference Call on November 16, 2023
EQS-News: Invitation to MorphoSys’ Third Quarter and First Nine Months 2023 Financial Results Conference Call on November 16, 2023
3 Healthcare Stocks That Have More Than Doubled in Value Since the Fed Started Raising Interest Rates
Last year, the Federal Reserve began hiking interest rates in an effort to slow down the economy. Today, interest rates are at their highest levels since the early 2000s. For many businesses, an
Is Sarepta Therapeutics Stock a Bad-News Buy?
Investing in biotech stocks is risky. And one of the more volatile ones of late is Sarepta Therapeutics (NASDAQ: SRPT). Shares of the company crashed last week after it released results from phase 3
2 Soaring Stocks to Buy and Hold
Biotech giant Regeneron (NASDAQ: REGN) and streaming specialist Roku (NASDAQ: ROKU) have been solid performers for most of the year, but both stocks recently jumped following their third-quarter
2 Soaring Stocks to Buy and Hold
Biotech giant Regeneron (NASDAQ: REGN) and streaming specialist Roku (NASDAQ: ROKU) have been solid performers for most of the year, but both stocks recently jumped following their third-quarter
2 Soaring Stocks to Buy and Hold
Biotech giant Regeneron (NASDAQ: REGN) and streaming specialist Roku (NASDAQ: ROKU) have been solid performers for most of the year, but both stocks recently jumped following their third-quarter
This Program for a Common Problem May Be Vertex Pharmaceuticals' Ticket to a New Wave of Billion-Dollar Revenues
Vertex Pharmaceuticals (NASDAQ: VRTX) generates billions of dollars in annual revenues from its treatments for the rare disease cystic fibrosis. And Vertex should continue to dominate in cystic
This Program for a Common Problem May Be Vertex Pharmaceuticals' Ticket to a New Wave of Billion-Dollar Revenues
Vertex Pharmaceuticals (NASDAQ: VRTX) generates billions of dollars in annual revenues from its treatments for the rare disease cystic fibrosis. And Vertex should continue to dominate in cystic
This Program for a Common Problem May Be Vertex Pharmaceuticals' Ticket to a New Wave of Billion-Dollar Revenues
Vertex Pharmaceuticals (NASDAQ: VRTX) generates billions of dollars in annual revenues from its treatments for the rare disease cystic fibrosis. And Vertex should continue to dominate in cystic
Biogen (BIIB) Q3 2023 Earnings Call Transcript
Image source: The Motley Fool.
Biogen (NASDAQ: BIIB)Q3 2023 Earnings CallNov 08, 2023, 8:00 a.m. ET
Operator
Source Fool.com
Biogen (BIIB) Q3 2023 Earnings Call Transcript
Image source: The Motley Fool.
Biogen (NASDAQ: BIIB)Q3 2023 Earnings CallNov 08, 2023, 8:00 a.m. ET
Operator
Source Fool.com
Biogen (BIIB) Q3 2023 Earnings Call Transcript
Image source: The Motley Fool.
Biogen (NASDAQ: BIIB)Q3 2023 Earnings CallNov 08, 2023, 8:00 a.m. ET
Operator
Source Fool.com
1 Gene Therapy Stock to Buy and Hold for the Long Haul
Biotech companies working on gene therapies have made significant strides lately, but many of them remain relatively risky stocks. Still, gene therapies have the potential to help transform medicine
Why CRISPR Therapeutics Stock Could Be About to Take Off
CRISPR Therapeutics (NASDAQ: CRSP) is a company that doesn't have an approved product on the market. Its operations are unprofitable, and it is burning through cash. There are many reasons that this
Why CRISPR Therapeutics Stock Could Be About to Take Off
CRISPR Therapeutics (NASDAQ: CRSP) is a company that doesn't have an approved product on the market. Its operations are unprofitable, and it is burning through cash. There are many reasons that this
Why CRISPR Therapeutics Stock Could Be About to Take Off
CRISPR Therapeutics (NASDAQ: CRSP) is a company that doesn't have an approved product on the market. Its operations are unprofitable, and it is burning through cash. There are many reasons that this